

Daniel Lawton Bio

Daniel is Chairman of the Board of Promentis Pharmaceuticals, Inc., a Milwaukee-based start up developing new therapies for the treatment of schizophrenia and other CNS disorders, a company for which he was the founding CEO. Daniel led Promentis until taking on the Group President role at Dohmen, where he led five Dohmen group companies in the life science services space.

Prior to joining Promentis, Daniel was General Counsel of Schwarz Pharma Inc. and centrally involved in a series of high-value transactions that led to the sale of Schwarz to UCB in 2006. Daniel was previously at Abbott Laboratories where he was Senior Counsel to both the domestic and international organizations.

Daniel is a graduate of the University of Michigan and Harvard Law School, and was a Teaching Fellow in economics under Professor Martin Feldstein at Harvard College.